Skip to content

Oruka Therapeutics, Inc. ORKA Weighted Average Exercise Price of Outstanding Options

Weighted Average Exercise Price of Outstanding Options at other companies

Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
$12.39+42.7%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
$15.07+25.9%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.03B+533%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s weighted average exercise price of outstanding options.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s weighted average exercise price of outstanding options?
Oruka Therapeutics, Inc. (ORKA) reported weighted average exercise price of outstanding options of $18.66 in Q1 2026.
How has Oruka Therapeutics, Inc.'s weighted average exercise price of outstanding options changed year-over-year?
Oruka Therapeutics, Inc.'s weighted average exercise price of outstanding options increased by 56.0% year-over-year, from $11.96 to $18.66.
What does weighted average exercise price of outstanding options mean?
This metric calculates the average price at which holders of outstanding stock options can purchase company shares. It provides context on the 'in-the-money' status of employee compensation packages. When compared to the current market price, it helps assess the alignment between employee incentives and shareholder value.